

DOI: 10.15419/bmrat.v5i7.456



Article History:

Received: 11 June 2018 Accepted: 30 June 2018 Published: 27 July 2018

Keywords:

Anti-hyperglycemic, Antioxidant, Diabetes, Glibenclamide, Phytochemical

Author for correspondence:

D. A. Omoboyowa e-mail: damlexb@gmail.com

Abstract

Pharmacological potential of methanol extract of *Anacardium occidentale* stem bark on alloxan-induced diabetic rats

D. A. Omoboyowa¹,

F. O. Afolabi 2 and T. C. Aribigbola 1

¹Biochemistry Unit, Department of Chemical Science, Ondo State University of Science and Technology, Okitipupa, Ondo State, Nigeria

²University Medical Centre, Ondo State University of Science and Technology, Okitipupa, Ondo State, Nigeria

Background: The anti-hyperglycemic potential of methanol stem bark extract of Anacardium occidentale (MSBEAO) was investigated using an alloxan-induced diabetic rat model. Alloxan administration induces the generation of free radicals which can affect antioxidant status resulting in the disruption of the β -cells of the pancreas. Therefore, this study examines the antioxidant potential of the plant extract and the ameliorating effect on the pancreas of alloxan-induced diabetic rats. Methods: Diabetes was induced by intraperitoneal injection of 150 mg/kg body weight of alloxan monohydrate. MSBEAO, at a concentration of 100 or 200 mg/kg b.w. was orally administered to alloxan-induced diabetic rats and normal rats. The hypoglycemic effect, oral glucose tolerance test, and biochemical assay of alloxan-induced diabetic rats were assayed using standard procedures. Results: Preliminary phytochemical screening of the extract revealed the presence of alkaloids, tannins, saponins, terpenoids, carbohydrates, and phenols at moderate concentrations. The lethality dose (LD50) of the plant extract was found to be equal to or less than 5000 mg/kg b.w. The hypoglycemic effect of the extract on the non-diabetic rats revealed a significant (p<0.05) decrease in the blood glucose concentration of animals administered with 1 g/kg b.w. of the extract, compared to normal control rats administered with normal saline. In the oral glucose tolerance test, the methanol extract exerted the highest response, similar to glibenclamide after 15 and 30 minutes of administration, compared to the control rats. The methanol extract yielded the highest blood glucose lowering effects after 9 days of treatment (p<0.05), compared to diabetic rats administered with normal saline and 0.3 mg/kg b.w. of glibenclamide. Administration of the extract at 200 mg/kg b.w. showed improved pancreas architecture and regeneration of the β -cells, compared with the pancreas of animals in the other groups. Conclusion: The results of this study suggest that MSBEAO is a potentially effective agent for the management of diabetes which might result from the antioxidant-generating capacity of the stem bark.



© 2018 The Authors. Published by the BioMedPress under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/ by/4.0/, which permits unrestricted use, provided the original author and source are credited.

1. Background

Diabetes mellitus (DM) is a type of metabolic disease in which there is a high blood glucose level over a prolonged period. It is a common endocrine disorder which is rapidly increasing in the human population all over the world [1]. Diabetes often leads to complications such as peripheral neuropathy, retinopathy, coronary heart disease, and cataract [2]. Persistent hyperglycemia causes increased generation of free radicals, especially reactive oxygen species, which may result from glucose auto-oxidation and protein glycosylation [3]. Free radicals play an important role in the causation and complication of diabetes mellitus through the alterations in endogenous free radical scavenging defense mechanisms. While chemotherapy remains the major solution to diabetes control, the setbacks being encountered in present anti-diabetic therapies calls for more innovative treatment therapies that are effective, less toxic, less expensive, and with fewer side effects compared to synthetic drugs [4].

Cashew (*Anacardium occidentale*) is a well-known member of the *Anacardiaceae* family and is commonly found in Northeastern Brazil [5]. The plant is commonly referred to as cashew in English, kashu in Hausa, and kaju in Yoruba. It has a thick and tortuous trunk with branches so winding that they frequently reach the ground [6]. The cashew tree produces many resources and products. All parts of the plants, like leaves, fruits, and bark, have been traditionally used to relieve a variety of ailments [7]. The kernel has been reported by Omoboyowa *et al.* [8] to possess anti-diarrheal effect with reversal of electrolyte imbalance in castor oil-induced diarrheal rats [5]. However, this study is aimed at evaluating the possible anti-diabetic potential of methanol extract of *Anacardium occidentale* stem bark on the blood glucose profile of alloxan-induced diabetic and normal rats.

2. Methods

(a) Plant Materials

The stem barks of *A. occidentale* were collected from trees within the Botanical Garden of Akanu Ibiam Federal Polytechnic, Unwana, Afikpo, Ebonyi State, Nigeria. The plant was authenticated by the Botany Department, University of Nigeria, Nsukka, Nigeria, where voucher specimens have been deposited (UNN/BOT/2016/058). The stem barks were shed dried and powdered for extraction. The air-dried powder was extracted using soxhlet extraction apparatus. One hundred and twenty grams (120 g) of the powder was extracted with 1000 ml of methanol for 48 hours. The extract obtained was evaporated under a vacuum evaporator. The yield of crude extract of *A. occidentale* stem bark was recorded to be 8.50 g (7.08 %). The extract was preserved in the refrigerator at 10°C during the experimental protocol. The methanolic extract of *A. occidentale* stem bark was prepared in normal saline for oral administration [9].

(b) Chemical Reagents and Drugs

All the reagents used in this study were of analytical grade, and the diagnostic kits used for the estimation of serum catalase, superoxide dismutase (SOD), and glutathione (GSH) were obtained from Randox Diagnostic (England). Alloxan was purchased from Sigma-Aldrich (India) and standard glibenclamide was supplied by New Good Health Pharmacy (Nigeria).

(c) **Animals**

Healthy male albino rats weighing 146 g and 196 g were procured from the Department of Veterinary Medicine, University of Nigeria Nsukka, Nigeria and maintained in standard animal cages at a temperature of 25 ± 5 °C with 12-hour light and dark cycle. The animal experiments were conducted as per the AIFPU Scientific Research Committee in Nigeria. The experimental protocol was approved by the Institutional Animal Ethics Committee. During the

2441

Biomed. Res. Ther. 2018, 5(7): 2440-2454

animal experiments, animals were fed with standard pellet diet and free water *ad libitum* and allowed to acclimatize for seven days before they were randomly grouped for the experiment. Fifteen rats were used for the hypoglycemic study while twenty-five rats were grouped for the acute anti-hyperglycemic study.

(d) Induction of Diabetes and Experimental Design

Diabetes was induced by intraperitoneal injection of alloxan monohydrate dissolved in normal saline at a dose of 150 mg/kg body weight in animals fasted overnight. After 48 hours, blood samples were collected from the tail vein and the blood glucose level was determined by a glucometer (AccuChek) [9]. The animals showing blood glucose level higher than 200 mg/dL were considered as hyperglycemic and selected for the studies. The animals were divided into five groups containing five animals in each group (n = 5) as follows:

Group 1 – Non-diabetic control

Group 2 - Alloxan-induced diabetic rats administered with 0.3 ml of normal saline

Group 3 - Alloxan-induced diabetic rats treated with 0.3 mg/kg b.w. of Glibenclamide

Group 4 - Alloxan-induced diabetic rats treated with 100 mg/kg b.w. dose of MSBEAO;

Group 5 - Alloxan-induced diabetic rats treated with 200 mg/kg b.w. dose of MSBEAO.

Glibenclamide was used as the reference standard during the studies. After 72 hours of induction of diabetes, the plant extract suspended in normal saline was administered for 9 days using an oral feeding needle. Blood samples were collected on days 0, 3, 6, and 9 from the start of the study for measurement of blood glucose via the tail vein. Blood glucose levels were measured by glucometer. After 9 days, blood samples were collected through the retro-orbital puncture and analyzed for selected antioxidants. The pancreases were also collected for histopathological studies.

(e) Phytochemical Test

The qualitative phytochemical screening of the methanol extract of *A. occidentale* stem bark was carried out using procedures outlined by Evans *et al.* [10].

(f) Acute Toxicity and Lethality (LD $_{50}$) Test

The acute toxicity and lethality of *MSBEAO* were determined using the method outlined by Omoboyowa *et al.* [9]. The test was divided into two phases. In phase one, sixteen (16) randomly selected adult mice were divided into four groups, four per group (n = 4), and received 100, 300, 600 or 1000 mg/kg body weight of methanol extract. Signs of toxicity and possible death were monitored and recorded for a period of 24 hours. After the 24-hour observation, the doses for the second phase were determined based on the outcome of the first phase. Since there was no death, a fresh batch of animals was used following the same procedure in phase 1 but with higher doses (of 1900, 2600 or 5,000 mg/kg body weight) of extract. The animals were also observed for 24 hours for signs of toxicity and possible death. The LD₅₀ was calculated as the geometric mean of the high non-lethal dose and lowest lethal dose [9].

(g) Glucose Profile Study

(i) Hypoglycemic Test in Non-Diabetic Rats

In this test, fifteen (15) non-diabetic rats were fasted overnight and divided evenly into three (3) groups. Group 1 rats were administered with 0.3 ml of normal saline, Group 2 rats were given 0.3 mg/kg body weight of glibenclamide, and Group 3 rats were given 1 g/mg body weight of MSBEOA. Blood samples were collected from the tail vein prior to and at 0, 1, 2, 3 and 5 hours after dosing, and used to estimate the glucose concentrations.

(ii) Oral Glucose Tolerance Test (OGTT) in Normal Rats

The procedure, dosage of extracts, normal saline and glibenclamide, and animal groupings in this study were as described in previous reports. In addition to the protocols, the rats were orally administered with glucose (2 g/kg body weight) 30 min after dosing, and blood samples were obtained via the tail vein at time 0 (prior to glucose dosing), at 15, 30, 45, 60, 90 or 120 min after glucose administration, to measure the glucose levels.

(iii) Acute Anti-Hyperglycemic Study

Glucose profile studies were conducted with non-diabetic rats and alloxan-induced diabetic rats as described by Atangwho *et al.* [11].

In this test, 4 groups of alloxan-induced diabetic rats were treated as follows: Group II received 0.3 ml of normal saline, Group III received 0.3 mg/kg body of Glibenclamide, Group IV received 100 mg/kg body weight of *MSBEAO*, Group V received 200 mg/kg *MSBEAO*, and Group 1 served as the normal control group. The extract, normal saline and glibenclamide were administered once per day during the 9-day period of the study. Fasting blood glucose (FBG) was measured on day 0 (baseline), and days 3, 6 and 9. At the end of the study, the animals were euthanized, and then the pancreas was removed and preserved for histology. The AccuCheck glucometer was used to measure blood glucose levels.

(h) Biochemical Assay

The concentrations of glutathione, malondialdehyde, and vitamin C, and catalase and superoxide dismutase activities were determined spectrophotometrically according to the Randox assay kit.

(i) Pancreas Histopathological Study

Dissected pancreas from control, diabetic and treated albino rats were fixed in 10% formaldehyde and processed, and used for histopathological analysis. Tissue processing was carried out using an autotechnicon and the prepared, 5 μ m thick sections were morphologically evaluated by an independent histopathologist, according to the method described by Ezejiofor *et al.* [12].

(j) Measurement of Body and Organ Weight

The body weight and weights of select organs (spleen, liver, kidney, and heart) were determined using high precision balance (HPB 2000-10 mg, China).

(k) Statistical Analysis

Statistical analyses of all the results were performed by one-way analysis of variance, followed by *post hoc* multiple comparison tests using the SPSS (version 16) software. Results were expressed as mean \pm standard error of mean (SEM). The statistical significance level was set at *p* < 0.05.

3. Results

(a) Lethal Dose (LD₅₀) Results

In the experiment, there was no lethality or behavioral changes in the three groups of the mice that received 10, 100, or 1000 mg/kg body weight of the *MSBEAO* at the end of the first experiment. Further dose increase to 1900, 2600 and 5000 mg/kg body weight of the extract did not induce death within 24 hours of administration. Together, these results showed that the extract was relatively safe at doses equal to or greater than 5000 mg/kg body weight.

2443

(b) Phytochemical Screening

The phytochemical study of *A. occidentale* stem bark revealed a high presence of tannins, saponins, terpenoids, carbohydrates, and phenols, a moderate presence of anthraquinones, but low presence of steroids, alkaloids, flavonoids, and reducing sugars, as indicated in **Table 1**.

Table 1. Qualitative Phytochemical Results of A. occidentale Stem Bark

Phytochemical Compounds	Result
Steroids	+
Alkaloids	+
Mayer's test	+
Wagner's test	
Tannins	+++
Saponins	++
Froth test	
Flavonoids	+
Terpenoids	++
Reducing sugars	+
Phenols	++
Anthraquinones	++
Carbohydrates	++
Benedict's test	++
Fehling's test	

KEY: + : Low Present; ++: moderate present

(c) Hypoglycemic Test in Non-Diabetic Animals

The effects of the methanol extract of *A. occidentale* stem bark and glibenclamide on the glucose levels of non-diabetic rats are shown in **Figure 1**. The diabetic animals administered with 0.3 mg/kg body weight of glibenclamide and 1 g/kg body weight of *MSBEAO* showed a significant (p<0.05) decrease in glucose levels throughout the experimental period as compared with normal control animals. The hypoglycemic effect of the standard drug (glibenclamide) was observed to be significantly (p<0.05) higher compared with that of the extract.

(d) Oral Glucose Tolerance Test on Non-Diabetic Rats

The effects of *MSBEAO* and glibenclamide on oral glucose tolerance test of non-diabetic rats are shown in **Figure 2**. The measured FBG reached its peak value 15 minutes after oral administration of glucose. Animals administered with 2 g/kg body weight of glucose and 0.3 mg/kg body weight of glibenclamide had the most significant (p<0.05) reduction in FBG; the reduction was sustained throughout all the measured times compared to the glucose levels of the other treatment groups. The animals administered with 2 g/kg body weight of glucose and 1 g/kg body weight of *MSBEAO* showed a significant (p<0.05) increase in glucose levels after 30 min of treatment compared to glucose levels after 15 min of treatment. There was also a significant (p<0.05) reduction in glucose levels after 45, 60, 90 and 120 min, respectively, compared to glucose levels after 30 min.




Figure 1. Effects of *A. occidentale* extract and glibenclamide on the hypoglycemic level of non-diabetic rats. NRN: Normal rats administered with 0.3 ml of normal saline. NRG: Normal rats administered with 0.3 mg/kg b.w. of glibenclamide. NRE: Normal rats administered with 1 g/kg b.w. of methanol stem bark extract of *A. occidentale*

(e) Body Weight of Treated and Non-Treated Alloxan-Induced Diabetic Animals

The effects of *MSBEAO* and glibenclamide on body weight of alloxan-induced diabetic rats are shown in Figure 3. Diabetic animals treated with 100 mg/kg body weight of *MSBEAO* showed a significant (p<0.05) increase in body weight on days 0, 3, 6 and 9, respectively, compared to animals treated with 0.3 mg/kg body weight of glibenclamide. Animals induced and treated with 200 mg/kg body weight of *MSBEAO* showed a significant (p<0.05) reduction in body weight on days 0, 3 and 6, respectively, compared to animals treated with 100 mg/kg body weight of *MSBEAO*.

(f) Weight of Selected Organs of Treated and Non-Treated Alloxan-Induced Diabetic Rats

The effects of *MSBEAO* and glibenclamide on weight of select organs (spleen, liver, kidney, and heart) in alloxan-induced diabetic rats are shown in **Figure 4**. Diabetic-induced animals treated with 0.3 mg/kg body weight of glibenclamide showed a significant (p<0.05) reduction in the weight of spleen, liver, kidney and heart, respectively, compared to animals treated with 0.3 ml of




Figure 2. Effects of *A. occidentale* extract and glibenclamide on oral glucose tolerance in non-diabetic rats. RGN: Rats administered with 2 g/kg b.w. of glucose and 0.3 ml of normal saline. RGG: Rats administered with 2 g/kg b.w. of glucose and 0.3 mg/kg b.w. of glibenclamide. RGE: Rats administered with 2 g/kg b.w. of glucose and 1 g/kg b.w. of methanol stem bark extract of *A. occidentale*

normal saline. Animals induced and treated with 100 mg/kg body weight of the extract showed a significant (p<0.05) increase in the weight of spleen, liver, kidney and heart, respectively, compared to animals treated with 0.3 mg/kg body weight of glibenclamide. Animals induced and treated with 200 mg/kg body weight of the extract showed a significant (p<0.05) reduction in the weight of spleen, kidney and heart, respectively, compared to weight of animals treated with 100 mg/kg body weight of the extract. There was also a significant (p<0.05) increase in the weight of liver, compared to that of animals treated with 100 mg/kg body weight of MSBEAO.

(g) Blood Glucose Levels of Treated and Non Treated Alloxaninduced Diabetic Animals

The effects of different dosages of *MSBEAO* on blood glucose levels in diabetic rats are illustrated in **Figure 5**. The animals treated with *MSBEAO* at 100 and 200 mg/kg b. w. showed significant (p<0.05) hypoglycemic activity on the 9th day compared with the diabetic control group. While the animals that received 100 mg/kg b. w. of the extract also showed non-significant (p>0.05) reduction in blood glucose concentration compared with the diabetic animals treated with 200 mg/kg b. w. of the extract. The animals that received glibenclamide at 0.3 mg/kg significantly (p<0.05) reduced the blood glucose level on the 9th day of the study compared with the diabetic control animals.




Figure 3. Effects of methanol extract of *A. occidentale* stem bark on body weight of alloxan-induced diabetic **rats**. ^aP< 0.05: Significant compared with NR; NR: Normal control rats; AIRANS: Alloxan-induced rats administered with 0.3 ml of normal saline; AIRAG: Alloxan-induced rats administered with 0.3 mg/kg b.w. of glibenclamide; AIRA100AO: Alloxan-induced rats administered with 100 mg/kg b.w. of methanol stem bark extract of *A. occidentale*; AIRA200AO: Alloxan-induced rats administered with 200 mg/kg b.w. of methanol stem bark extract of *A. occidentale*

(h) Effect of Methanol Extract of A. occidentale Stem Bark on Antioxidant Parameters of Alloxan-Induced Diabetic Rats

The alloxan-induced diabetic rats treated with 0.3 mg/kg body weight of glibenclamide and 100 mg/kg body weight of *MSBEAO* showed a significant (p<0.05) reduction in serum malondialdehyde concentration compared to the diabetic-induced animals administered with 0.3 ml of normal saline. The diabetic animals treated with 0.3 mg/kg body weight of glibenclamide and 100 mg/kg body weight of the extract showed a significant (p<0.05) reduction in vitamin C concentration and catalase activity compared to the alloxan-induced animals administered with 0.3 ml of normal saline. The glutathione concentration in the diabetic rats treated with 200 mg/kg body weight of the extract was significantly (p<0.05) higher compared to the diabetic animals treated with 100 mg/kg body weight of *MSBEAO* (**Table 2**).

(i) Histopathology of the Pancreas

The prepared slides were examined with a MoticTM compound light microscope using 4X, 10X and 40X objective lenses. The photomicrographs were taken using a MoticTM 9.0 megapixels microscope camera at 100X and 400X magnifications.




Figure 4. Effects of methanol extract of *A. occidentale* stem bark on organ weight of select organs in alloxaninduced diabetic rats. NR: Normal control rats; AIRANS: Alloxan-induced Rats administered 0.3 ml of normal saline; AIRAG: Alloxan-induced Rats administered 0.3 mg/kg b. w of glibenclamide; AIRA100AO: Alloxan-induced Rats administered 100 mg/kg b. w of methanol stem bark extract of *A. occidentale*; AIRA200AO: Alloxan-induced Rats administered 200 mg/kg b. w of methanol stem bark extract of *A. occidentale*

Treatmen M	Malondialdehyde (mg/ml)	Superoxide dismutase (µl)	Glutathione (mg/dl)	Vitamin C (mg/dl)	Catalase (µl)
NR	2.80 ± 0.20	1.13 ± 0.002	4.20 ± 0.10	2.26 ± 0.05	$\begin{array}{r} 6.45 \pm \\ 0.04 \end{array}$
AIRANS	$6.55\pm0.25^{*}$	$0.91\pm0.01^*$	3.85 ± 0.15	2.28 ± 0.03	$10.02 \pm 0.10^{*}$
AIRAG	$4.80\pm0.10^{*}$	1.11 ± 0.01	$5.65\pm0.05^*$	$1.97\pm0.13^*$	$5.57 \pm 0.20^{*}$
AIRA100AC	$5.70 \pm 0.20^{*}$	$1.06\pm0.007*$	$2.50\pm0.50^*$	$1.81\pm0.04^*$	$7.00 \pm$
AIRA200AC	$5.05 \pm 0.25^{*}$	$1.09\pm0.008^*$	4.05 ± 0.15	$1.94\pm0.04^*$	$0.08 \\ 12.85 \pm \\ 0.16$

Table 2. Select antioxidant status of alloxan-induced diabetic rats treated with MSBEAO

All values are expressed as Mean \pm SEM (n = 5); *P<0.05 compared with NR. NR: Normal control rats; AIRANS: Alloxan-induced rats administered with 0.3 ml of normal saline; AIRAG: Alloxan-induced rats administered with 0.3 mg/kg b.w. of glibenclamide; AIRA100AO: Alloxan-induced rats administered with 100 mg/kg b.w. of methanol stem bark extract of *A. occidentale;* AIRA200AO: Alloxan-induced rats administered with 200 mg/kg body weight of methanol stem bark extract of *A. occidentale*




Figure 5. Effects of methanol extract of *A. occidentale stem bark* on glucose level of alloxan-induced diabetic **rats.** ^aP< 0.05: Significant compared with NR; NR: Normal control; AIRANS: Alloxan-induced rats administered with 0.3 ml of normal saline; AIRAG: Alloxan-induced rats administered with 0.3 mg/kg b.w. of glibenclamide; AIRA100AO: Alloxan-induced rats administered with 100 mg/kg b.w. of methanol stem bark extract of *A. occidentale;* AIRA200AO: Alloxan-induced rats administered with 200 mg/kg b.w. of methanol stem bark extract of *A. occidentale;* AIRA200AO:




Plate 1: **Normal Control Rats.** Sections of the pancreas collected from animals in this group showed a normal histo-architecture of both the exocrine and endocrine pancreases. The pancreatic lobules contained normal sized pancreatic islets (arrow) which are composed of a cluster of pale eosinophilic cells with eccentrically located nuclei and abundant cytoplasm. Exocrine pancreas (EP); H&E 100X and 400X.




Plate 2: Alloxan-Induced Rats Administered with 0.3 ml of Normal Saline. Sections of the pancreas collected from animals in this group showed a normal histo-architecture of the exocrine pancreas. The endocrine pancreas showed a decrease in the number and size of the pancreatic islets (arrow). The few observed pancreatic islets (arrow) were relatively inconspicuous; H&E 100X and 400X.






Plate 3: Alloxan-Induced Rats Administered with 0.3 mg/kg b.w. of Glibenclamide. Sections of the pancreas collected from animals in this group showed a normal histo-architecture of the exocrine pancreas. As observed in Group 2 above, the endocrine pancreas showed a decrease in the number and size of the pancreatic islets (arrow). However, the few observed pancreatic islets (arrow) were relatively hypercellular (H&E 100X and 400X).

4. Discussion

Diabetes mellitus is a metabolic disease associated with impaired glucose metabolism which adversely alters the intermediary metabolism of lipids and carbohydrate. It is a chronic metabolic disorder of carbohydrate, fat and protein metabolism, characterized by elevation of both fasting and postprandial blood glucose levels [13]. In the present study, the anti-hyperglycemic activity of the methanol extract of *A. occidentale* stem bark was evaluated in alloxan-induced diabetic and normal rats, using fasting blood glucose test. The results showed that serum glucose concentration in diabetic rats treated with 100 mg/kg and 200 mg/kg of extract was reduced significantly (p<0.05), and the blood glucose lowering effects of the extract were traceable to its constituents.

While saponins are known to have anti-hyperglycemic effect, flavonoids have been found to be an active principle in herbal medicine and are known to be powerful antioxidants that may protect organs against toxicity and potential damage due to agents such as alloxan [14]. The induced 2450








Plate 5: Alloxan-Induced Rats Administered with 200 mg/kg b.w. of MSBEAO. Sections of the pancreas collected from the animals in this group showed normal histo-architecture of the exocrine pancreas. The endocrine pancreas showed a decrease in the number and size of the pancreatic islets (arrow). However, the few observed pancreatic islets (arrow) were relatively hypercellular (compared to Group 2), comprising of numerous tiny cells with hyperchromatic nuclei and poorlydemarcated cytoplasm. These cells did not have the characteristics of β -cells, and may be comprised of other cell populations in the islets (H&E 100X and 400X).

Biomed. Res. Ther. 2018, 5(7): 2440-2454

weight loss observed in diabetic untreated rats, as a result of alloxan injection and compared to treated rats, mimic the common weight loss usually diagnosed in clinical diabetic patients. During the 9 days of treatment, continuous reduction in body weight of alloxan-induced diabetic rats was observed, whereas a significant (p<0.05) gain in body weight was observed in *A. occidentale*-treated rats. The treatment with *A. occidentale* extract ameliorated the loss in body weight and restored this level towards normal.

The potential of *A. occidentale* extract to correct the body weight might result from its antihyperglycemic ability by increasing the rate of glucose metabolism. Insufficient insulin secretion prevents the body from obtaining glucose from the blood into the body's cells to be metabolized as energy. Therefore, the body starts to mobilize fat and muscle for energy, causing a reduction in overall body weight. The ability of *A. occidentale* extract to reduce hyperglycemia and protect against muscle wasting might increase the availability of glucose for energy production, thereby restoring body weight.

The present study examines the antioxidant potential of methanol stem bark extract of *A. occidental* in alloxan-induced diabetes rats. The results showed a high level of antioxidant potential which may play an important role in the management of disorders involving oxidative stress. Plants containing natural antioxidants, such as tannins, flavonoids, vitamin C and vitamin E, can preserve β -cell function and prevent diabetes-induced formation of reactive oxygen species, leading to inhibition of lipid peroxidation [9,14].

The anti-hyperglycemic properties of *MSBEAO* may be possible due to insulin-released stimulating effects and uptake of peripheral glucose, which in turn reverse alloxan-induced hyperglycemia. However, islet lesions and destruction of β -cells were evident in the untreated hyperglycemic group. Treatment with *MSBEAO* results in the proliferation of β -cells and reversal of islet lesions. This results in the upregulation of insulin secretion, inducing a reduction in hyperglycemia as observed in treated animals. The β -cells, which are the insulin- secreting cells, make up over 80% of the total number of cells in the pancreatic islets.

Alloxan causes necrosis of the β -cells of the pancreatic islets. This is the reason why there is a decrease in the number and the size of the pancreatic islets. In this study, the observations of Groups 1 (untreated control), 2 (alloxan only) and 3 (alloxan and standard drug) were as expected. However, the observations in the treated groups were unexpected. First, the low dose groups showed decreased size of the hypercellular islets, while the high dose groups showed relatively normal sized pancreatic islets. In the literature, β -cells are not known to regenerate in adult subjects but the findings in the high dose groups suggest that regeneration of β -cells may have occurred.

5. Conclusions

A. occidentale stem bark extract possessed anti-hyperglycemic activity like the standard drug used in this study. This was based on its prominent reduction of blood glucose levels in the animals treated with different doses compared with the untreated diabetic animals. The observed anti-hyperglycemic potential of the plant extract may be attributed to the presence of bioactive compounds and antioxidant-generating capacity. However, the results of this study justify the traditional use of the plant in the treatment of diabetes.

6. Open Access

This article is distributed under the terms of the Creative Commons Attribution License (CCBY4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

7. List of abbreviations

DM: Diabetes mellitus; FBG: Fasting blood glucose; GSH: Glutathione; LD50: Lethal dose 50; MSBEAO: Methanol stem bark extract of Anacardium occidentale; SOD: Superoxide dismutase; SPSS: Statistical package for social sciences

8. Ethics approval and consent to participate

The animal experiments were conducted as per the AIFPU Scientific Research Committee in Nigeria.

9. Competing interests

The authors declare that they have no conflicts of interest.

10. Authors' contributions

This work was carried out in collaboration between all authors. Authors DAO, FOA and TCA designed the study, wrote the protocol and supervised the work. Authors DAO and TCA carried out all laboratories work. Author DAO performed the statistical analysis. Authors DAO and FOA managed the analyses of the study. Authors DAO and FOA wrote the first draft of the manuscript. Authors DAO and TCA managed the literature searches and edited the manuscript. All authors read and approved the final manuscript.

11. Acknowledgments

The authors are grateful to Mr. Eguonu M. O. and Dr. Ezeasor K. C. of the Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, University of Nigeria, Nsukka for the preparation and interpretation of the pancreas histopathology.

References

- 1. Andrade M, Helnrich N. 2005 The Rising Global Burden of Diabetes and its Complication. *European Journal of Cardiovascular Prevention and Rehabilitation* **17**, 3–8.
- 2. Matsuda H, Murakami T, Yashiro K, Yamahara J, Yoshikawa M. 1999 Antidiabetic principles of natural medicines. IV. Aldose reductase and qlpha-glucosidase inhibitors from the roots of Salacia oblonga Wall. (Celastraceae): structure of a new friedelane-type triterpene, kotalagenin 16-acetate. *Chemical & Pharmaceutical Bulletin* **47**, 1725–9.
- Moussa SA. 2008 Oxidative stress in Diabetes mellitus. *Romanian Journal of Biophysics* 18, 225– 35.
- 4. Iqbal N. 2007 The burden of type 2 diabetes: strategies to prevent or delay onset. 3, 511-20.
- 5. Omoboywa DA, Nwodo OF, Joshua PE, Akalonu CX. 2015 Effect of chloroform-ethanol extracts of cashew (Anacadium occidentale) kernel on electrolyte imbalance in castor oil induced diarrhea rats. *International Journal of Biochemistry Research & Review* 8, 1–6.
- 6. Adesokan A, Oyewole I, Turay B. 2009 Kidney and liver function Parameters in Alloxan induced Diabetic Rat Treated with Aloe Barbadenesis juice Extract. **1**, 33–7.
- 7. Dare SS, Hamman O, Musa A. 2011 Effects of Aqueous Extract of Anacardium occidentale (cashew) leaf on pregnancy outcome of wister Rat. International. *Journal of Animal and Veterinary Advances* **3**, 77–82.
- 8. Omoboyowa DA, Nwodo OF, Joshua PE. 2013 Anti-diarrhoeal activity of chloroform-ethanol extracts of cashew (Anacadium occidentale) kernel. *Journal of Natural Products* 6, 109–17.
- 9. Omoboyowa DA, Igara EC, Otuchristian G, Olugu KD. 2016 Antidiabetic activity of methanolic extract of seed cotyledon of Chrysophyllum albidum in alloxan-induced diabetic rats. *Biokemistri* 28, 88–95.
- 10. Evans WC. 2009 Trease and EvansPharmacognosy E-Book.

- 11. Atangwho IJ, Egbung GE, Ahmad M, Yam MF, Asmawi MZ. 2013 Antioxidant versus antidiabetic properties of leaves from Vernonia amygdalina Del. growing in Malaysia. *Food Chemistry* **141**, 3428–34.
- 12. Ezejiofor AN, Okorie A, Orisakwe OE. 2013 Hypoglycaemic and tissue-protective effects of the aqueous extract of persea americana seeds on alloxan-induced albino rats. **20**, 31–9.
- 13. Hussain MA, Theise ND. 2004 Stem-cell therapy for diabetes mellitus. Lancet 364, 203-5.
- 14. Hunt JV, Smith CC, Wolff SP. 1990 Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. *Diabetes* **39**, 1420–4.